High molecular weight polyethylene glycol cellular distribution and PEG-associated cytoplasmic vacuolation is molecular weight dependent and does not require conjugation to proteins

Toxicologic Pathology

Volumn 41, Issue 7, 2013, Pages 970-983

  Rudmann, Daniel G ^a   Alston, James T ^a   Hanson, Jeffrey C ^a   Heidel, Shawn ^b  

^a ELI LILLY AND COMPANY   (United States)

^b Lead Optimization Toxicology and Pharmacology   (United States)

Author keywords

immunohistochemistry; pathology; polyethylene glycol; rat; toxicity; vacuolation

Indexed keywords

DRUG CARRIER; HIGH MOLECULAR WEIGHT POLYETHYLENE GLYCOL; IMMUNOGLOBULIN G; MACROGOL; PROTEIN; TUMOR NECROSIS FACTOR BINDING PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTOPSY; BRAIN; CELL VACUOLE; CHOROID PLEXUS; CONTROLLED STUDY; CYTOPLASM; DRUG CONJUGATION; DRUG DOSE INCREASE; EPITHELIUM CELL; HALF LIFE TIME; HAPLORHINI; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KIDNEY TUBULE EPITHELIUM; KUPFFER CELL; LIVER CELL; MACROPHAGE; MOLECULAR WEIGHT; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; TISSUE DISTRIBUTION; TOXICITY TESTING;

IMMUNOHISTOCHEMISTRY; PATHOLOGY; POLYETHYLENE GLYCOL; RAT.; TOXICITY; VACUOLATION;

ANIMALS; CHOROID PLEXUS; IMMUNOHISTOCHEMISTRY; KIDNEY; LUNG; MACACA FASCICULARIS; MALE; MOLECULAR WEIGHT; POLYETHYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY; VACUOLES;

EID: 84884271622     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623312474726     Document Type: Article

References (20)

1. Armstrong J. K., Hempel G., Koling S., Chan L. S., Fisher T., Meiselman H. J., Garratty G.. Antibody against poly (ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer. 2007 ; 110: 103-11
2. Bendele A., Seely J., Richey C., Sennello G., Shopp G.. Renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins. Toxicol Sci. 1998 ; 42: 152-57
3. BLA #125160. Certolizumab pegol (CIMZIA). February 26, (2006): p. 5, 43, 71-72.
4. Broadwell R. D., Salcman M.. Expanding the definition of the blood-brain barrier to protein. Proc Natl Acad Sci. 1981 ; 78: 7820-24
5. Cesta M. F.. Normal structure, function, and histology of the spleen. Toxicol Pathol. 2006 ; 34: 455-65
6. Cheng T., Chuang K., Chen B., Roffler S. R.. Analytical measurement of PEGylated molecules. Bioconjug Chem. 2012 ; 23: 881-99
7. Elliott V. L., Edge G. T., Phelan M. M., Lian L., Webster R., Finn R. F., Park B. K., Kitteringham N. R.. Evidence for metabolic cleavage of a PEGylated protein in vivo using multiple analytical methodologies. Mol Pharm. 2012 ; 9: 1291-301
8. EMEA/664021/2009. Certolizumab pegol (CIMZIA), (2009): p. 14.
9. Gursahani H., Riggs-Sauthier J., Pfeiffer J., Lechuga-Ballesteros D., Fishburn C. S.. Absorption of polyethylene glycol (PEG) polymers: The effect of PEG size on permeability. J Pharm Sci. 2009 ; 98: 2847-56
10. Harris J. M., Chess R. B.. Effects of PEGylation on pharmaceuticals. Nat Rev Drug Discov. 2003 ; 2: 214-21
11. Hu X., Olivier K., Polack E., Crossman M., Zokowski K., Gronke R. S., Parker S., Li Z., Nestorov I., Baker D. P., Clarke J., Subramanyam M.. In vivo pharmacology and toxicology evaluation of polyethylene glycol-conjugated interferon β-1a. J Pharmacol Exp Ther. 2011 ; 338: 984-96
12. Menkhorst E., Salamonsen L., Robb L., Dimitriadis E.. IL11 antagonist inhibits stromal differentiation, causing pregnancy failure in mice. Biol Reprod. 2009 ; 80: 920-27
13. Pavenstadt H., Kriz W., Kretzler M.. Cell biology of the glomerular podocyte. Physiol Rev. 2003 ; 83: 253-307
14. Ruifrok A. C., Johnston D. A.. Quantification of histochemical staining by color deconvolution. Anal Quant Cytol Histol. 2001 ; 23: 291-99
15. Swirski F. K., Nahrendorf M., Etzrodt M., Wildgruber M., Cortez-Retamozo V., Panizzi P., Figueriredo J., Kohler R. H., Chudnovskiy A., Waterman P., Aikawa E., Mempel T. R., Libby P., Weissleder R., Pittet M. J.. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science. 2009 ; 325: 612-16
16. Tsai N., Cheng T., Roffler S. R.. Sensitive measurement of polyethylene glycol-modified proteins. Biotechniques. 2001 ; 30: 396-402
17. Webster, R., Elliott, V., Park, B. K., Walker, D., Hankin, M., and Taupin, P. (2009). PEG and PEG conjugates toxicity: Towards an understanding of the toxicity of PEG and its relevance to PEGylated biologicals. In PEGylated Protein Drugs: Basic Science and Clinical Applications (F. M. Veronese, ed.), pp. 127146. Birkhauser Verlag, Basel, Switzerland.
18. White C. A., Zhang J., Salamonsen L. A., Baca M., Fairlie W. D., Metcalf D., Nicola N. A., Robb L., Dimitriadis E.. Blocking LIF action in the uterus by using a PEGylated antagonist prevents implantation: A nonhormonal contraceptive strategy. Proc Natl Acad Sci USA. 2007 ; 104: 19357-62
19. Yamaoka T., Tabata Y., Ikada Y.. Distribution and tissue uptake of poly (ethylene glycol) with different molecular weights after intravenous administration to mice. J Pharm Sci. 1994 ; 83: 601-606
20. Young M. A., Malavalli A., Winslow N., Vandegriff K. D., Winslow R. M.. Toxicity and hemodynamic effects after single dose administration of MalPEG-hemoglobin (MP4) in rhesus monkeys. Transl Res. 2007 ; 149: 333-42